SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Alamar Biosciences, Inc. (ALMR) News

Track canonical SquawkNews coverage tagged to ALMR, Alamar Biosciences, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 7 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol ALMR Asset equity Sector Markets 90 days 7 Last 32.915 Updated Sep 24, 2026, 10:53 PM UTC Open live news feed
L Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemabFREMONT, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. NASDAQ:AL NEWS | Sep 24, 2026, 10:53 PM UTC L Alamar Biosciences to participate in Morgan Stanley Global Healthcare Conference Alamar Biosciences said it will participate in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference. EQUITY | Sep 01, 2026, 08:07 PM UTC L ALMR - Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference ALMR - Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference EQUITY | Sep 01, 2026, 08:06 PM UTC L Alamar Biosciences appoints Robert Ragusa to board Alamar Biosciences named Robert Ragusa a Class I director effective September 1, 2026, and added him to its audit, compensation and nominating and corporate governance committees. REGULATION | Sep 01, 2026, 08:04 PM UTC L Crinetics, Alamar, Halozyme Report Earnings Crinetics, Alamar, and Halozyme report better-than-expected Q2 financial results EARNINGS | Aug 12, 2026, 12:58 PM UTC L Stifel Maintains Buy on Alamar Biosciences, Raises Price Target to $32 Stifel analyst Daniel Arias maintains Alamar Biosciences (NASDAQ: ALMR ) with a Buy and raises the price target from $28 to $32. EQUITY | Aug 11, 2026, 05:41 PM UTC L Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum Alamar Biosciences Inc. (NASDAQ: ALMR ) shares are trading higher on Tuesday as the company is expanding its global partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures. The proteomics company is e EARNINGS | Aug 11, 2026, 05:25 PM UTC